Publication & Citation Trends
Publications
0 total
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T Cell Activation in Tumors. OA
Cited by 30
Semantic Scholar
483 Preclinical evaluation of JTX-1484, an anti-LILRB4 antagonist antibody, for re-programming of immunosuppressive myeloid cells OA
Cited by 0
Semantic Scholar
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody OA
Cited by 30
Semantic Scholar
ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control OA
Cited by 12
Semantic Scholar
945 Overlapping and distinct patterns of LILRB receptors support complementary targeting approach in cancer OA
Cited by 0
Semantic Scholar
217 Evaluating biomarkers of JTX-8064 (anti-LILRB2/ILT4 monoclonal antibody) in an ex vivo human tumor histoculture system to inform clinical development
Cited by 2
Semantic Scholar
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models OA
Cited by 31
Semantic Scholar
Abstract 5536: ICOS hi CD4 T cells emerging on vopratelimab treatment have Th1 central memory characteristics and may contribute to durability of clinical responses
Cited by 0
Semantic Scholar
Research Topics
Lymphoma Diagnosis and Treatment
(14)
DNA Repair Mechanisms
(12)
Cancer-related Molecular Pathways
(11)
Immune Cell Function and Interaction
(11)
T-cell and B-cell Immunology
(8)
Affiliations
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
Boston Children's Hospital
Howard Hughes Medical Institute
Harvard University
University of Trieste